Combination treatment employing a survivin inhibitor with currently used modalities may prove to be clinically beneficial by selectively increasing overall tumor kill or possibly lowering the dose of chemotherapeutic agents needed to effectively treat Rb lesions. Here, BIRC5 is linked to neoplasm.